Algert Global LLC bought a new stake in Meridian Bioscience, Inc. (NASDAQ:VIVO) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 21,531 shares of the company’s stock, valued at approximately $301,000. Algert Global LLC owned 0.05% of Meridian Bioscience as of its most recent SEC filing.
A number of other hedge funds also recently modified their holdings of VIVO. Advisor Group Inc. raised its holdings in shares of Meridian Bioscience by 24.9% during the second quarter. Advisor Group Inc. now owns 7,720 shares of the company’s stock valued at $122,000 after buying an additional 1,537 shares during the last quarter. Hartford Investment Management Co. bought a new stake in Meridian Bioscience during the third quarter worth approximately $166,000. Eqis Capital Management Inc. bought a new stake in Meridian Bioscience during the third quarter worth approximately $184,000. Nisa Investment Advisors LLC raised its holdings in Meridian Bioscience by 90.9% during the fourth quarter. Nisa Investment Advisors LLC now owns 13,020 shares of the company’s stock worth $182,000 after purchasing an additional 6,200 shares in the last quarter. Finally, UBS Asset Management Americas Inc. raised its holdings in Meridian Bioscience by 0.7% during the second quarter. UBS Asset Management Americas Inc. now owns 13,091 shares of the company’s stock worth $206,000 after purchasing an additional 92 shares in the last quarter. Institutional investors own 85.37% of the company’s stock.
Several equities analysts have weighed in on VIVO shares. Canaccord Genuity lifted their price objective on shares of Meridian Bioscience from $14.00 to $16.00 and gave the stock a “hold” rating in a research report on Friday, January 26th. Zacks Investment Research cut shares of Meridian Bioscience from a “buy” rating to a “hold” rating in a report on Sunday, January 21st. Finally, BidaskClub cut shares of Meridian Bioscience from a “hold” rating to a “sell” rating in a report on Saturday, February 3rd.
Shares of Meridian Bioscience, Inc. (VIVO) opened at $14.30 on Tuesday. The stock has a market cap of $602.89, a price-to-earnings ratio of 20.96 and a beta of 0.98. The company has a quick ratio of 3.96, a current ratio of 5.82 and a debt-to-equity ratio of 0.28. Meridian Bioscience, Inc. has a 52 week low of $12.45 and a 52 week high of $16.45.
Meridian Bioscience (NASDAQ:VIVO) last released its earnings results on Thursday, January 25th. The company reported $0.15 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.14 by $0.01. The firm had revenue of $52.30 million during the quarter, compared to analyst estimates of $49.00 million. Meridian Bioscience had a net margin of 10.46% and a return on equity of 17.00%. The business’s revenue was up 11.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.15 EPS. research analysts forecast that Meridian Bioscience, Inc. will post 0.69 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, February 15th. Stockholders of record on Monday, February 5th will be given a dividend of $0.125 per share. This represents a $0.50 dividend on an annualized basis and a dividend yield of 3.50%. The ex-dividend date of this dividend is Friday, February 2nd. Meridian Bioscience’s dividend payout ratio is currently 98.04%.
COPYRIGHT VIOLATION WARNING: This news story was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of international copyright & trademark laws. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/02/13/algert-global-llc-buys-shares-of-21531-meridian-bioscience-inc-vivo.html.
Meridian Bioscience Company Profile
Meridian Bioscience, Inc is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers.
Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.